Brought to you by 
Bayer and Lion Bioscience look for new drugs, diagnostics
22 Feb 2000
Executive Summary
Bayer will collaborate with Heidelberg-based Lion Bioscience (sequencing and biocomputing services) in a five-year research agreement. Bayer will make precommmercial payments totaling up to $50-60mm, including an up-front equity investment, technology access fees, R&D money (estimated at $25-30mm), and set-up funds for a new subsidiary named Lion Bioscience Research Inc.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com